Crossmark

Immune checkpoint blockade in desmoplastic melanoma

Crossref DOI link: https://doi.org/10.1038/s43018-026-01118-1

Published Online: 2026-02-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mo, George

Mitchell, Tara C. https://orcid.org/0000-0002-8186-7284
License Information

Text and Data Mining valid from 2026-02-06

Version of Record valid from 2026-02-06
More Information

Article History

First Online: 6 February 2026

Competing interests

: T.C.M. reports scientific advisory board participation for BMS, Merck and Tempus. G.M. reports no competing interests.